Hormone therapy coupled with GnRH agonism has yielded positive results in patients with BML.78 GnRH agonists not only suppress the ovarian steroidogenesis but also inhibit aromatase.85 A randomized, controlled clinical trial comparing the effects of aromatase inhibitor letrozole and GnRH agonist triptorelin on uterine leiomyoma volume showed a volume reduction with both therapies, with a slighter advantage of letrozole over triptorelin86. The gene discussed is CYP19A1; the disease is Uterine leiomyoma.